Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID)

• Main Authors: Kevin V. Kwee (Author), Jean-Luc Murk (Author), Qiqi Yin (Author), M. Birgitte Visch (Author), Linda Davidson (Author), Elke M. G. J. de Jong (Author), Juul M. P. A. van den Reek (Author), Milan Tjioe (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background The risk of SARS-CoV-2 infection does not appear to be increased for psoriasis patients using biologics compared to those on other treatments, but evidence is still limited. Objectives (1) to estimate the prevalence of SARS-CoV-2 infection in patients with psoriasis, (2) to compare SARS-C...